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Introduction {#sec1}
============

Synucleinopathies are characterized by the gradual appearance of intraneuronal inclusion bodies, termed Lewy bodies (LBs). These conditions encompass Parkinson\'s disease (PD) as well as PD dementia (PDD) and dementia with Lewy bodies (DLB) ([@bib8]). The latter two entities are characterized by the presence of LBs in hippocampal neurons and associated memory circuits ([@bib22]). In accord with such a distribution, cognitive deficits including impaired learning and memory are important clinical features of PDD and DLBs. LBs are intraneuronal protein aggregates composed of crowded organelles and lipid membranes and the protein alpha-synuclein (α-Syn) ([@bib30]; [@bib32]). The exact mechanism of α-Syn-induced neuronal dysfunction and death remains elusive, but prior research implicated changes in neurotrophic factor signaling and neuronal energy metabolism during pathological changes. In addition, cell-to-cell transmission of α-Syn through extracellular vehicles (EVs) likely contributes to the spread of pathology in these conditions. The molecular factors that control neuronal EV release are therefore likely to contribute to LB progression.

FGFs are a family of pleiotropic growth and differentiation factors that regulate CNS homeostasis in health and disease. Although FGFs are best known for their roles in the early steps of patterning the neural primordium and proliferation of neural progenitors, they have equally important roles in the adult brain, where they regulate neuronal calcium homeostasis and plasticity further promoting neuroprotection and repair in response to neural tissue damage. In addition to these physiological roles, basic fibroblast growth factor (bFGF) has been linked with responses to neuronal injury ([@bib7]; [@bib35]; [@bib41]; [@bib11]) or to psychiatric conditions ([@bib37]; [@bib5]). In addition to these well-known roles of bFGF, we have recently demonstrated bFGF-controlled release of EVs from hippocampal neurons ([@bib16]). Because of these functions, bFGF may likewise affect LB-associated pathological changes.

Here, we investigated the cell lysate (CL) and EV proteome changes of hippocampal neurons in response to bFGF. Using high-resolution mass spectrometry (MS), we quantified differentially expressed proteins (DEPs) in the CL and EV fractions of bFGF-treated hippocampal neurons. To capture the protein interactions among these DEPs, we adapted a weighted protein co-expression network analysis (WPCNA) methodology and probed the subsequent co-expression modules for LBP-associated proteins. This approach allowed us to extract LBP-enriched modules and revealed the molecular interactions between bFGF signaling and LBP-associated molecular changes. We specifically identified LBP-related RNA-binding proteins (PD-RBPs), numerous ion channels and receptor proteins, and α-Syn interacting proteins as interactome components that connect bFGF signaling to α-Syn pathology. Therefore, our results will support the investigation of bFGF signaling in α-Syn-associated pathological changes.

Results {#sec2}
=======

Characteristic CL and EV Proteome Changes Are Induced by bFGF {#sec2.1}
-------------------------------------------------------------

In order to examine bFGF-induced proteome changes in the CL and in EVs, we treated hippocampal neurons for 24 h with bFGF (50 ng/mL) and subjected the CL and EV fraction to high-resolution mass spectrometry (MS) (see [Transparent Methods](#mmc1){ref-type="supplementary-material"} for experimental details) ([Figure 1](#fig1){ref-type="fig"}A). Primary rat hippocampal neurons from E18 CD (Sprague Dawley) rat embryos were used for all experiments. All experiments were performed by using at least biological triplicates and exhibited very strong Pearson correlation coefficients (r ∼ 0.98--1) among the replicates, demonstrating a high reproducibility in both CL and EV datasets ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). All proteins were detected at least thrice in the technical replicates of control and bFGF-treated samples. These criteria identified n = 5,314 and n = 2,258 proteins for the CL and EV fraction, respectively. We next performed an unsupervised clustering using principal component analysis (PCA) on CL and EV proteomic datasets. As expected, we found a clear separation between the two conditions ([Figure 1](#fig1){ref-type="fig"}B), and Euclidian distance-based hierarchical clustering confirmed these findings ([Figure 1](#fig1){ref-type="fig"}C). Next, we analyzed the differential expression of proteins (DEPs) to define the proteomic signature from CL and EV. This analysis yielded a set of n = 1,660 and n = 650 DEPs in CL and EV fractions ([Tables S1](#mmc2){ref-type="supplementary-material"}A and S1B). Taken together, our results demonstrate that bFGF extensively affects the expression of a large number of proteins in the CL and EVs from primary hippocampal neurons.Figure 1Evaluation of Proteomic Changes in bFGF-Treated Rat Brain Hippocampal Primary Neurons(A) Schematic representation of proteomic data collection from rat hippocampal primary neurons cell lysate (CL) and extracellular vesicles (EV). The protein expression data were used to perform network and Lewy body pathology enrichment analysis.(B) Principal component analysis (PCA) based on CL and EV pellet proteome datasets. Total three-dimensional PCA plotting as 86.8% of variance (PC1 = 82.03%, PC2 = 3.47%, PC3 = 1.37%).(C) The dendrogram represents the hierarchical clustering based on the Euclidean distances computed from log~2~ LFQ intensities.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Co-expression Analysis Organized Proteome-wide Changes in CL and EV into Modules {#sec2.2}
--------------------------------------------------------------------------------

Next, we performed WPCNA on proteins differentially expressed in response to bFGF ([Figure S2](#mmc1){ref-type="supplementary-material"}). Co-expression module analysis yielded nine CL (M~CL~1--M~CL~9) and four modules EV (M~EV~1--M~EV~4) modules from CL (n = 5,314) and EV (n = 2258) proteome datasets, respectively ([Figures 2](#fig2){ref-type="fig"}A and 2B). To further examine the bFGF-induced proteome signature, the statistically significant, differentially expressed proteins (sDEPs) were mapped to the co-expression modules. Among the CL modules, M~CL~2 and M~CL~8 depicted the highest sDEP signature ([Figure 2](#fig2){ref-type="fig"}C), and of the four EV modules, M~EV~1, M~EV~2, and M~EV~3 were found with the strongest sDEPs signature ([Figure 2](#fig2){ref-type="fig"}D). These sDEP modules were considered for further analysis ([Tables S2](#mmc3){ref-type="supplementary-material"}A and S2B). In WPCNA analysis, modules are represented by a weighted expression profile (Eigenprotein) of co-expressed proteins. To test the expression pattern of each sDEP module, we computed module Eigenprotein values and found an increased expression of proteins in M~CL~2 and M~EV~2 and 3 modules, whereas modules M~CL~8 and M~EV~1 showed a decreased expression in response to bFGF treatment ([Figures 2](#fig2){ref-type="fig"}E and 2F). An additional module preservation analysis demonstrated that co-expression modules from both datasets were strongly preserved, with a Z-summary score above 10, in comparison with random modules ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Next, we sought to identify the common modules and computed Jaccard similarity co-efficient between the CL and EV. This analysis indicated a higher overlap between the M~EV~1 and the M~CL~8 module ([Figure 2](#fig2){ref-type="fig"}G), and both modules had down-regulated proteins in response to bFGF treatment. Next, we explored the common interactions of key regulatory proteins (so-called hubs) in the M~CL~8 and M~EV~1. Hub proteins play an important role in regulating biological functions and are identified in common modules by calculating the module membership (MM) of each protein combined with protein interaction network analysis (see [Transparent Methods](#mmc1){ref-type="supplementary-material"} section). These analyses identified *Gpi, Glul, Aldoc, Ldhp, Pygp*, and *Prdx6* (we used the rat gene symbol nomenclature for each protein throughout the text) as the six main down-regulated hub proteins ([Figure 2](#fig2){ref-type="fig"}H). The main interaction partners of hub proteins in the corresponding CL modules were *Lrrc47, Cd44, Cald1, Xpo1, Pja2*, and *Micu2*. A pathway enrichment analysis of the common modules (M~CL~8 and M~EV~1) revealed a huge number of biological functions for these proteins ([Figure 2](#fig2){ref-type="fig"}I). In sum, these results provided an initial modular assessment of the bFGF-incited proteomic changes in hippocampal neurons.Figure 2WPCNA Analysis of Cell Lysate (CL) and Extracellular Vesicles (EV) bFGF Induced Proteomes(A) Dendrogram clusters CL proteins (n = 5,314) into nine modules.(B) The dendrogram groups EV proteins (n = 2,258) into three co-expression modules.(C and D) The bar plots represent the enrichment of differentially expressed proteins (DEP) signatures in CL and EV co-expression modules; x and y axis denote the modules and percentage overlap of the DEP signature (∗∗∗p ≤ 0.01, negative log~10~ Benjamini-Hochberg adjusted p values; Fisher\'s exact test).(E and F) Module expression profiles of two CL and three EV modules (Wilcoxon test p value: 0.0034, 0.00094), respectively.(G) Module resemblance between each set of modules was assessed by the Jaccard similarity co-efficient between their sets of CL and EV modules. See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.(H) The module plot shows the common module the M~EV~1 and M~CL~8 modules based on the high Jaccard similarity coefficient.(I) The most significant (negative log~10~ p ≤ 0.05) biological processes gene ontology (GO) terms of common module between CL and EV. Note: red and blue colors indicate up- and down-regulation, respectively. Gene symbols corresponding to proteins are used as labels in the module plot.

Proteins Linked to Lewy Body Pathologies Are Enriched in CL and EV Co-expression Modules {#sec2.3}
----------------------------------------------------------------------------------------

We next mined the proteins that associate to Lewy body pathologies (LBPs) from the widely published PD literature and intersected them with our co-expression modules in order to explore LBP-related proteins among the bFGF-exhorted modules ([Figure 1](#fig1){ref-type="fig"}A). We endorse that associative likelihood of these results may be more for LBP due to the aforementioned clinical features of PD and primary hippocampal neurons as a source of datasets used in this study. We found M~CL~2 and M~CL~8 and M~EV~1 and M~EV~3 modules to be significantly (BH corrected p value ≤ 0.05) enriched with the LBP molecular signature ([Figures 3](#fig3){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}). The assimilation of markers from genome-wide association studies (GWASs) and proteome-wide data permits the identification of potential molecular mechanisms in disease modules. Thus, we compiled 15 statistically significant LBP-GWAS studies (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}) and intersected them with bFGF-incited sDEP modules. Again, we found a higher degree of overlap with GWAS datasets in M~CL~2 and 8 and in M~EV~1 and 3 ([Tables S3](#mmc4){ref-type="supplementary-material"}A and S3B). All LBP modules consisted of up- and down-regulated proteins further contributing to a substantial level of heterogeneity among the interacting proteins, where M~CL~8 and M~EV~3 were more heterogeneous as compared with M~CL~2 and M~EV~1 in terms of up- or down-regulated proteins ([Figure S4](#mmc1){ref-type="supplementary-material"}). For a better understanding of this heterogeneity we conducted a module-wise pathway enrichment analysis revealing module-specific up- and down-regulated pathways ([Figure 3](#fig3){ref-type="fig"}B).Figure 3Enrichment of Lewy Body Pathology (LBP) Linked RNA-Binding Proteins (RBPs) in Cell Lysate (CL) and Extracellular Vesicles (EV) Co-expression Modules(A) The bar plots show Lewy body pathology proteins enrichment in CL and EV co-expression modules. See also [Figure S4](#mmc1){ref-type="supplementary-material"} (Note: The y axis of bar plot denotes negative log~10~ Benjamini-Hochberg adjusted p values, Fisher\'s exact test, dotted line represents the statistical significance 1.31, is comparable with the p values ≤ 0.05).(B) Biological processes enrichment analysis on LBP Co-expression modules both CL (left-side) and EV (right-side).(C and D) Module plots representing the RNA-binding proteins and their interacting partners of LBP modules from both CL and EV up and down biological processes enrichment of each module. Note: Red and blue colors denote up and down-regulation, respectively. Gene symbols matching to proteins are used as labels in the LBP-RBPs modules.

bFGF Modulates the Abundance of LBP-Associated RNA-Binding Proteins {#sec2.4}
-------------------------------------------------------------------

Next, we examined the role of disease-associated pathological processes in these modules. Altered RNA metabolism is associated with familial PD ([@bib20]). Therefore, we screened our data for LBP-related RNA-binding proteins (LBP-RBPs). This analysis revealed LBP-RBPs in the CL (M~CL~2 = 8; M~CL~8 = 4) and EV (M~EV~1 = 3; M~EV~3 = 1) modules, thus allowing us to construct LBP-RBPs interaction modules in each dataset and determine hub-RBPs along with their respective enriched pathways ([Figures 3](#fig3){ref-type="fig"}C and 3D). In the CL, *Rps6*, *Eef2*, *Srp14*, *Gspt1*, *Ddx6*, *Lars*, *Atxn2*, and *Rps14* were found as the key up-regulated LBP-RBPs, whereas *Hnrnpa2b1*, *Hnrnph3*, *Fus*, and *IIf2* were key down-regulated LBP-RBPs. In the EV fraction, *Aco1*, *Eef2*, and *Hnrnpa2b1* were key down-regulated LBP-RBPs and *Rps14* was a key up-regulated LBP-RBP. From the cellular and subcellular location analysis of hub LBP-RBPs, we found up-regulated proteins like *Rps6* localize mainly to mitochondria, *Eef2* localizes to the plasma membrane and cytosol, *Srp14* to nucleoli, *Gspt1* and *Atxn2* to the cytosol, *Ddx6* to cytoplasmic bodies, *Lars* to nuclear bodies, and *Rps14* to the endosomal reticulum and cytosol. Most of the nucleoplasm LBP-RBPs are down-regulated except for *Eef2* (localized to the plasma membrane and cytosol) and *Aco1* (found in mitochondria and cytosol). In summary, these results suggest an effect of bFGF on a variety of LBP-associated RBPs located to distinct cellular compartments.

bFGF Predominantly Affects the Abundance of LBP-Associated Metabotropic Receptors {#sec2.5}
---------------------------------------------------------------------------------

In addition to RBPs, neuronal ion channels and receptors contribute to α-Syn-associated pathological changes in LBP ([@bib34]). Therefore, we next investigated the effect of bFGF on metabotropic and ionotropic receptors in our data. Two sets of (ionotropic) AMPA receptor subunits were found within the up-regulated LBP-M~CL~2-module (n = 12) and in the down-regulated LBP-M~CL~8 (n = 10) module with *Nptx2* (M~CL~2) and *Gria1* or *Gria2* (M~CL~8) as corresponding intramodular hubs. Ionotropic NMDA receptors were detected for the down-regulated LBP-M~CL~8 (n = 7) module with *Grin2b* as intramodular hub. A number of up-regulated metabotropic adrenergic receptors were found in the LBP-M~CL~2 (n = 20) module with *Nedd4* as an intramodular hub and down-regulated dopamine receptors were found in the LBP-M~CL~8 (n = 6) module with *Cnr1* as an intramodular hub ([Figure 4](#fig4){ref-type="fig"}A). Limited LBP-related glutamate receptors were detected in the down-regulated LBP-M~EV~1 (n = 2) module from the EV fraction, whereas LBP-related adrenergic and opioid receptors were found in the up-regulated LBP-M~EV~3 module (n = 7 and n = 14, respectively) ([Figure 4](#fig4){ref-type="fig"}B). The strength between the protein interactions was determined by computing a connectivity score; metabotropic adrenergic receptors and ionotropic glutamatergic AMPA receptors were strongly connected in the CL modules ([Figure 4](#fig4){ref-type="fig"}C). In the EV modules, a high connectivity was observed for metabotropic opioid and adrenergic receptors ([Figure 4](#fig4){ref-type="fig"}D). Jaccard similarity analysis enabled the identification of an up-regulated M~CL~2 module and M~EV~3 module as a common module, suggesting a linearized protein exodus as EV content for LBP-related receptors ([Figure 4](#fig4){ref-type="fig"}E). Only the down-regulated LBP-M~CL~8 module (n = 11) has shown ion channel enrichment with slightly less down-regulation of *Scn2a* as intramodular hub ([Figure 4](#fig4){ref-type="fig"}F). Taken together, our analyses suggest that predominantly metabotropic receptor-associated molecules are pledged in response to treatment with bFGF along with a small subset of ionotropic glutamate receptors.Figure 4Association of Ionotropic, Metabotropic Receptors and Ion Channel in Lewy Body Pathology (LBP) Modules(A and B) The module plots show CL and EV LBP ionotropic and metabotropic receptor and their interacting partners. Note: Edges/interactions between the proteins (gene symbols corresponding to proteins are used as labels) represent the correlation between them.(C and D) Connection strength of ionotropic, metabotropic receptors (CL, EV) modules analyzed using connectivity score represented as a pairwise matrix.(E) Pairwise similarity of ionotropic, metabotropic receptors between the CL and EV LBP modules was evaluated using Jaccard similarity co-efficient.(F) The module view of the CL LBP ion channel and its interactions.

bFGF Influences the Molecular Assembly of α-Syn-Interaction in LBP {#sec2.6}
------------------------------------------------------------------

Among the detected ion channel receptors and channels, we found *Nedd4* and *Tln1* as key α-Syn interaction partners. Because of the α-Syn role in LBP the dataset was examined for additional α-Syn interaction partners ([Figure 5](#fig5){ref-type="fig"}A). We identified α-Syn interacting proteins in our LBP modules using information reported in [@bib15]; this protruded to a α-Syn interaction network (pSIN) ([Figure 5](#fig5){ref-type="fig"}B). There were 20 overlapping proteins in all modules of which 3 overlapped between EV and pSIN, 8 between CL-pSIN, 106 between EV-CL PD-modules, and 9 (*Vdac1*, *Abca1*, *Rab6a*, *Nucb1*, *Aldh2, Nedd4*, *Tln1*, *Mapk1*, and *Rps14*) among all subsets ([Figure 5](#fig5){ref-type="fig"}B) ([Table S4](#mmc5){ref-type="supplementary-material"}). For a comprehensive sketch of these protein interactions, we further examined 50 immediate interactions of the overlapping 115 proteins, obtaining an α-Syn interaction network using STRING database ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). In order to further examine the interactome between LBP and bFGF signaling, we developed an overall composite module (CM) among LBP-associated receptors, ion channels, RBPs, α-Syn interacting partners, and key players in the EV-CL modules ([Figure 5](#fig5){ref-type="fig"}C). The CM was heterogeneously composed of both up-/down-regulated proteins and key proteins that were extracted from CM by estimating various centrality dimensions ([Figure S6](#mmc1){ref-type="supplementary-material"}). This comprehensive centrality analysis has concluded the shortest-path-betweenness-centrality as a key parameter. This enabled us to mine the top 5% informative proteins, including *Scrn1*, *Slc6a11, Slc1a2*, *Tnr* (down-regulated) and *Rps14, Vim, Slc44a1* (up-regulated) ([Figure 5](#fig5){ref-type="fig"}D). The functional enrichment of the composite module was further characterized by pathway enrichment analysis ([Figure 5](#fig5){ref-type="fig"}E). Based on these results, we concluded that these proteins represent key components of the molecular interface of bFGF-signaling and LBP.Figure 5Amelioration of Alpha-Synuclein (α-Syn) Protein and Construction of Composite LBP Module(A) Outline describing the workflow for generating common modules.(B) Venn diagram showing the overlap between the LBP module proteins from CL, EV, and alpha-synuclein protein interacting partners.(C) A composite LBP co-expression module (CM) illustrating the interactions between the common LBP proteins from common CL, EV, alpha-synuclein protein interacting partners and receptors, ion channel, RNA-binding proteins. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.(D) The bar plot shows the top 5% of informative proteins from the composite module based on the shortest path betweenness centrality.(E) The statistically significant (negative log~10~ p value ≤ 0.05, hypergeometric test from METASCAPE) biological processes enrichment of the composite LBP module. Note: Red and blue color denote up- and down-regulation, respectively. Gene symbols related to proteins are used as labels in the CM plot.

bFGF-Enhanced EV-Release Possibly Supplements LBP Progression {#sec2.7}
-------------------------------------------------------------

Because of the sequential progression of pathology to defined brain regions in LBP, we finally mapped the presence of LBP module proteins to major brain regions suggested in [@bib31] ([Figures 6](#fig6){ref-type="fig"}A and [S7](#mmc1){ref-type="supplementary-material"}). LBP modules from CL and EV were appreciated in brain regions like the optic nerve, cerebellum, corpus callosum, olfactory lobe, brain stem and hippocampus. Conversely, we did not find a significant amount of proteins matched for the prefrontal cortex, striatum, and thalamus. We attributed this to sample collection from hippocampal neurons and, possibly, to variations in rat and mouse proteomic homologs. Within LBP proteins of various brain regions, we examined the coherent candidates in CL-EV modules ([Figure 6](#fig6){ref-type="fig"}B). For the cerebellum, we found a total number of 30 proteins in both CL-EV LBP-modules, and among these, two were shared with an overall partaking candidature of 6.67% for the designated brain region. Similarly, in the corpus callosum (25 proteins; 4 shared in the EV-CL PD-modules), optic nerve (72 proteins; 4 shared), hippocampus (23 proteins; 2 shared), and olfactory bulb (13 proteins; 2 shared) have earned an overall candidature of 16%, 5.56%, 8.7%, and 15.38% respectively. We made use of these shared candidates ([Table S5](#mmc6){ref-type="supplementary-material"}) to develop a composite protein interaction module (CPIM) along with the α-Syn interacting partners and other common PD proteins of EV-CL ([Figures S8](#mmc1){ref-type="supplementary-material"}A and S8B). By assessing the centrality parameters ([Figure S8](#mmc1){ref-type="supplementary-material"}C) we identified the top 5% informative proteins of CPIM based on shortest path betweenness centrality. *Scrn1*, *Slc6a11, Slc1a2*, and *Tnr* were among the top down-regulated and *Slc44a1*, *Rps14* were the most informative up-regulated proteins in the CPIM ([Figure S8](#mmc1){ref-type="supplementary-material"}D). Submodular analysis revealed *Aldh2*, *Mcat*, *Abca1*, *Ppp3ca*, *Slc32a1*, *Mapk1,* and *Prdx2* as top α-Syn interacting proteins, supporting a bilateral interaction with the most informative top down-regulated proteins identified in CPIM and *Atxn2*, *Gmps, Nedd4* as α-Syn-related interactions with top most informative up-regulated proteins ([Figures 6](#fig6){ref-type="fig"}C and [S8](#mmc1){ref-type="supplementary-material"}E). We counter-validated the implications of bFGF-induced expression in our study and found up-regulated modules M~CL~2 and M~EV~3 significantly enriched for pathology associated hub-molecules identified in postmortem brain tissues of patients with LB disease ([Figures S9](#mmc1){ref-type="supplementary-material"}A and S9B). Taken together, these results imply that, in a disease state an EV-mediated cross talk among various brain regions is supported from these results, which could involve transport of misfolded proteins via EVs and can affect the protein metabolism beyond the host at recipient brain region eventually claiming shutdown of neuronal molecular mechanisms and neurodegeneration.Figure 6Influence of α-Syn Protein Interactions in Brain-Specific Regions(A) Schematic representation of the workflow to generate brain region-specific LBP modules.(B) Doughnut plot shows the percentages of common brain region-specific proteins between the CL and EV LBP modules. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.(C) The module characterizes interactions between top 5% informative proteins of common brain region-specific module and their interactions with alpha-synuclein protein interacting partners. Note: Gene symbols associated to proteins are used as labels in the modules.See also [Figure S8](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Here we performed a global proteomic evaluation of bFGF effect induced to the CL and EV fractions from cultured hippocampal neurons and reasoned out its relevance in LBP ([Figure 1](#fig1){ref-type="fig"}). Instead of individual protein analysis, we rather applied a system-level comprehensive approach to examine bFGF-regulated DEPs using WPCNA ([Figure 2](#fig2){ref-type="fig"}). Because of the role of neurotrophic factors in hippocampal pathology, we screened our WPCNA-derived modules for proteins linked to LBP-associated molecular changes. This strategy enabled us to capture LBP modules ([Figures 3](#fig3){ref-type="fig"}A and [Tables S3](#mmc4){ref-type="supplementary-material"}A and S3B) and allowed intersecting bFGF- with LBP-related proteome changes. Our data identified n = 532, bFGF-induced DEPs associated to LBP molecular changes thus revealing a molecular network of LBP-associated proteins and their modulation by bFGF in hippocampal neurons. Our results will therefore support the investigation of neurotrophic signaling in LBP pathology onset and progression.

The top 5% up-regulated α-Syn interacting proteins shown in our results were *Rps14, Vim*, and *Slc44a1* ([Figure 5](#fig5){ref-type="fig"}D). Ribosomal protein *Rps14* has been reported to be differentially regulated in mitochondria of neural stem cells from patients with PD; under ribosomal stress this protein contributes to mitochondrial fragmentation ([@bib43]). Similar to PD-GWASs ([@bib14]) our analysis confirms the up-regulation of the *Slc44a1* (choline transporter-like protein-1) in response to bFGF treatment. It is shown that *Slc44a1* might be involved in mitochondrial energy metabolism ([@bib23]). Remarkably, a decrease of choline uptake reported in old adults ([@bib4]) and in α-Syn overexpressing animals ([@bib39]) further establishes the association of bFGF-induced proteomic changes to LBP. Finally, up-regulation of *Vim* in response to bFGF is correlated with PD ([@bib38]). *Scrn1*, *Slc6a11, Slc1a2*, and *Tnr* were among the top down-regulated CPIM proteins. In line with its role in PD, *Scrn1* is another α-Syn interaction partner involved in synaptic vesicle recycling, ER modulation, and calcium homeostasis ([@bib18]). *Scrn1* interactions with the vesicle-associated membrane protein (VAMP)-associated protein (VAP) and association of VAP low levels in PD further suggest a pathological relevance for *Scrn1* ([@bib26]). In summary, these proteins are strongly associated with PD and their modulation by bFGF may provide more molecular substrates for the effect of bFGF in LBP. *Slc1a2* has been investigated for polymorphic associations with PD ([@bib1]). *Slc6a11* has been demonstrated to modulate basal ganglia neuronal networks ([@bib3]), and *Tnr* may likewise contribute to PD pathology ([@bib36]). In conclusion, these results will provide the molecular basis for further studies to address the role of bFGF-induced proteomic changes in LBP.

In addition to the CPIM-derived top 5%, numerous additional candidate genes from our data have a potential pathogenic relevance for LBP. For instance, our data demonstrated an up-regulation of *Nptx2* ([Figure 4](#fig4){ref-type="fig"}A). This protein is involved in excitatory synapse formation. It also plays a role in clustering of AMPA-type glutamate receptors at established synapses, resulting in non-apoptotic cell death of dopaminergic nerve cells. In accord with the relevance of glutamate receptors, we found a down-regulation of AMPA (*Gria1* and *Gria2*) and NMDA (*Grin2b*) receptors, which is associated with the accelerated aging of neurons ([@bib6]). Likewise, we found a down-regulation of the glutamate transporter 2 gene *Slc1a2*, possibly further contributing to a dysregulated glutamate metabolism. Notably, *Nptx2* has been found to be present in LBs of patients with PD ([@bib24]), possibly implicating bFGF signaling in LB formation. Another example comes from the alterations of the mTOR and growth factor signaling pathways ([@bib21]) and impaired autophagy in LBP. Earlier, we confirmed the role of *Nedd4*-family E3 ligases in mTOR signaling ([@bib13]) and it has been reported that the ubiquitination of *Nedd4* by E3-ligases controls autophagy mechanisms ([@bib33]) and activation of the inflammasome ([@bib19]). Up-regulation of *Nedd4* in our data ([Figures 4](#fig4){ref-type="fig"}A and 4B) thus implicates the role of bFGF in modulating autophagy during LBP. In accord, *Nedd4* ubiquitination has been shown to suppress autophagy in neuroblastoma cells ([@bib40]) possibly impairing neuronal clearance mechanisms. Furthermore, *Nedd4* ligases rapidly promote ubiquitination of α-Syn ([@bib25]), further supporting a role of bFGF in α-Syn-mediated pathogenic mechanisms. In concurrence to such hypothesis, we observed new and formerly unknown interactions of *Tln1* (up-regulated) with *Nedd4* and *Nptx2* ([Figure 4](#fig4){ref-type="fig"}A). *Tln1* is known as integrin-associated cytoskeletal protein and has binding sites for other cytoskeletal proteins such as α-*Synemin*, helping them to unfold. In addition, *Tln1* regulates functions like cell proliferation, survival, and migration ([@bib28]). The upstream and downstream status of these proteins requires a further validation and may support the understanding of protein misfolding mechanisms ([@bib24]).

Interestingly, many of these LBP-associated proteins exhibited a similar behavior in the CL and EV fraction, i.e., up-regulated CL proteins were up-regulated in the EV fraction and vice versa. We attribute this finding to the mechanism of EV formation during the generation of multivesicular bodies (MVBs), where highly abundant proteins are more likely to be excreted by EVs ([@bib10]). In accord with an EV-mediated transmission of LBP-associated proteins, our data suggest a high representation of the top 5% proteins in CPIM and CM for olfactory bulb (OB) and corpus callosum (CC) ([Figures 6](#fig6){ref-type="fig"}B and 6C) ([@bib42]; [@bib27]), suggesting a connection of the pathogenic molecular network between these regions. In accord, the OB is considered as an entry for environmental pathogens that may induce LBP changes in the OB that are then transmitted to central brain areas, as an occurrence via EVs ([@bib2]). Along these lines, the loss of CC volume in patients with PD has been associated with cognitive impairment ([@bib9]).

Taken together, our study identifies a number of proteomic network changes and individual protein candidates that result from growth factor signaling and their potential contribution to LBP. Future experimental studies should investigate these candidates and assess their contribution to Lewy body-associated pathological changes *in vitro* and *in vivo*. This will ultimately strengthen the connection between growth factor signaling and LBP and allow assessment of growth factor signaling as a potential therapeutic target in LBP. In summary, these results will support the examination of bFGF for modulating disease progression in LBP and its cell-to-cell spreading, which has become a common theme for understanding disease progression in neurodegenerative conditions.

Limitations of the Study {#sec3.1}
------------------------

A limitation of our study is the absence of wet-lab experimental data from an LBP disease model. However, there is currently no rat model that replicates Lewy pathology well in its complexity ([@bib29]; [@bib12]). Because our earlier results on the effect of bFGF ([@bib17]) were derived from rat neurons, using more abundant mouse models would add additional bias. Taken together, we thus believe that intersecting "real-world" human proteomic alterations derived from databases with the effects of growth factor treatment in healthy rat primary neurons allows for a less confounded investigation of its true cellular effects. Future studies should validate our results in experimental disease model *in vitro* and *in vivo* as well as in postmortem material from human cases.

Resource Availability {#sec3.2}
---------------------

### Lead Contact {#sec3.2.1}

Any questions or requests should be addressed to the Lead Contact (<thomas.koeglsperger@dzne.de>).
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